# 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

> **NCT03732352** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- EGFR Gene Amplification
- EGFR Gene Mutation
- Glioblastoma
- Recurrent Glioblastoma
- Supratentorial Glioblastoma
- TP53 Wt Allele

## Interventions

- **OTHER:** Fludeoxyglucose F-18
- **DRUG:** Osimertinib
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT03732352
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-28
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732352, "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03732352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*